Technology
Health
Biotechnology

Calithera Biosciences

$6.68
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.18 (2.77%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CALA and other stocks, options, ETFs, and crypto commission-free!

About

Calithera Biosciences, Inc. engages in discovering and developing small molecule drugs that that target novel and critical metabolic pathway in tumor and cance-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. Read More The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Employees
73
Headquarters
South San Francisco, California
Founded
2010
Market Cap
248.52M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
332.32K
High Today
$6.87
Low Today
$6.48
Open Price
$6.48
Volume
189.83K
52 Week High
$7.45
52 Week Low
$3.55

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical
2014 IPO

News

Seeking AlphaMar 8

Calithera Biosciences (CALA) CEO Susan Molineaux on Q4 2018 Results - Earnings Call Transcript

Calithera Biosciences (NASDAQ:CALA) Q4 2018 Earnings Conference Call March 7, 2019 4:30 PM ET Company Participants Jennifer McNealey - Vice President, Investor Relations and Strategy Susan Molineaux - Founder, President and Chief Executive Officer Stephanie Wong - Senior Vice President, Finance Keith Orford - Chief Medical Officer Conference Call Participants Matt Phipps - William Blair Srikripa Devarakonda - Citigroup Jonathan Chang - SVB Leerink Operator Good day, ladies and gentlemen and thank...

62
Associated PressMar 5

Calithera to Present at Cowen & Company 39th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan M. Molineaux, Ph.D, the company’s founder, president and chief executive officer, will present at the Cowen & Company 39th Annual Healthcare Conference at 10:40 a.m. ET on Tuesday, March 12, 2019 in Boston. T...

20
Markets InsiderFeb 21

Calithera Biosciences Initiates Phase 1 Trial of Arginase Inhibitor CB-280 for the Treatment of Cystic Fibrosis

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it has initiated a Phase 1 clinical trial with CB-280, a novel, orally dosed arginase inhibitor being developed for the treatment of cystic fibrosis (CF). “The initiation of this Phase 1 study with CB-280 marks a...

84

Earnings

-$0.52
-$0.38
-$0.23
-$0.09
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.49 per share
Actual
-$0.51 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.